Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Imatinib Mesylate in Completely Resected High-Risk GIST
NCT00025246Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2001
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Started Sep 2001; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00025246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025246.